Will the development of the DBV-Technologies Viaskin patch enable us to bid goodbye to allergies?

Huge strides are being made in the field of epicutaneous immunotherapy. Click here if you’d like to discover more about the Paris firm that’s leading the charge.

Increasing numbers of individuals suffer from one or more allergy. Frequently-occuring allergies cover everything from nuts and eggs to shellfish.

DBV Technologies has been at the forefront of new research in the field in the shape of the Viaskin platform.

The Viaskin patch is a simple adhesive patch worn on the skin. The essential elements of the patch include an electrostatically-charged backing and an adhesive crown.

The strategy behind the patch is surprisingly simple. An antigen is sprayed onto the patch using electrospray technology. This creates an even layer of dry antigens.An ultra-moisturizing ‘condensation chamber’ formed between patch and skin allows these protein compounds to reach the tolerogenic Langerhans cells, where they begin the work of gradually desensitizing the body to these antigens.

Amongst the different patches being tested is a milk allergy treatment, about which you can find out more at http://www.dbv-technologies.com/en/viaskin-products/Viaskin-milk.